BRUNETTO, MAURIZIA ROSSANA
 Distribuzione geografica
Continente #
NA - Nord America 20.616
EU - Europa 5.878
AS - Asia 2.406
AF - Africa 126
SA - Sud America 25
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 5
Totale 29.071
Nazione #
US - Stati Uniti d'America 20.045
IT - Italia 1.630
CN - Cina 1.531
SE - Svezia 1.167
BG - Bulgaria 1.032
CA - Canada 570
DE - Germania 443
UA - Ucraina 421
VN - Vietnam 397
GB - Regno Unito 276
FI - Finlandia 210
CH - Svizzera 183
FR - Francia 172
HK - Hong Kong 131
TR - Turchia 123
RU - Federazione Russa 117
AT - Austria 90
SG - Singapore 69
CI - Costa d'Avorio 67
IN - India 62
BE - Belgio 35
NL - Olanda 23
SN - Senegal 20
RO - Romania 17
JP - Giappone 16
BR - Brasile 14
AU - Australia 12
IR - Iran 12
PK - Pakistan 12
CZ - Repubblica Ceca 11
NG - Nigeria 11
KR - Corea 10
GR - Grecia 9
EG - Egitto 8
ES - Italia 8
TW - Taiwan 8
ET - Etiopia 7
ID - Indonesia 7
IQ - Iraq 7
HU - Ungheria 6
CL - Cile 5
EU - Europa 5
IE - Irlanda 5
PL - Polonia 5
DK - Danimarca 4
MR - Mauritania 4
PE - Perù 4
PH - Filippine 4
TH - Thailandia 4
MD - Moldavia 3
MY - Malesia 3
NZ - Nuova Zelanda 3
AR - Argentina 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
IL - Israele 2
KE - Kenya 2
NP - Nepal 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BN - Brunei Darussalam 1
DZ - Algeria 1
HR - Croazia 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MX - Messico 1
NO - Norvegia 1
UG - Uganda 1
Totale 29.071
Città #
Fairfield 3.080
Woodbridge 3.041
Ann Arbor 1.791
Houston 1.744
Ashburn 1.445
Seattle 1.234
Sofia 1.032
Cambridge 1.007
Wilmington 965
Chandler 930
New York 681
Milan 640
Beijing 567
Jacksonville 564
Ottawa 555
Princeton 439
Lawrence 428
Medford 353
Des Moines 327
Nanjing 272
Bern 175
San Diego 167
Dearborn 160
Dong Ket 151
Frankfurt am Main 129
Hong Kong 122
Nanchang 122
Izmir 103
Jüchen 99
Vienna 88
Serra 87
Ogden 80
Kunming 78
Abidjan 66
Shenyang 64
Changsha 63
Florence 58
Hefei 56
London 52
Hebei 49
Pisa 48
Redwood City 48
Rome 48
Washington 42
Jiaxing 41
Boulder 40
Tianjin 40
Norwalk 39
Brussels 29
Pune 29
Jinan 26
Lancaster 24
Los Angeles 24
Dakar 20
Falls Church 20
Bremen 19
Boardman 17
Verona 16
Orange 15
Shanghai 15
Lucca 13
Auburn Hills 12
Guangzhou 12
Hangzhou 11
Xian 11
Kilburn 10
Marseille 10
Paris 10
Council Bluffs 9
San Francisco 9
Chengdu 8
Prague 8
Redmond 8
Singapore 8
Taipei 8
Changchun 7
Düsseldorf 7
Chicago 6
Detroit 6
Indiana 6
Lagos 6
Phoenix 6
Simi Valley 6
Bucharest 5
Budapest 5
Cairo 5
Edinburgh 5
Haikou 5
Helsinki 5
Lanzhou 5
Nürnberg 5
Toronto 5
Wuhan 5
Zhengzhou 5
Chaoyang 4
Chehalis 4
Chongqing 4
Dallas 4
Dublin 4
Ferrara 4
Totale 23.940
Nome #
Active HBV replication in HBsAg carriers with chronic Delta infection 180
Development of a liver model using PAM scaffolds in static and dynamic conditions 167
Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen 159
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 158
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound 155
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study 155
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen 152
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment 144
Sequence variation in hepatitis C viral isolates 142
A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers 137
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B 134
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier 133
Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? 132
A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease 131
Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D 131
Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay 131
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 129
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview 127
'e' antigen defective hepatitis B virus and course of chronic infection 127
REPLICATING AND VIRION SECRETING HEPATITIS B MUTANT VIRUS UNABLE TO PRODUCE PRES2 PROTEIN 126
Hepatitis delta virus, a model of liver cell pathology 126
High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders 125
Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization 124
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations 123
T-lymphocyte response to hepatitis C virus in different clinical courses of infection 122
Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects 122
Software and expert system for the management of chronic hepatitis B 122
Potential applications of extracorporeal photopheresis in liver transplantation 121
A multiphase model of th dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alfa2a, lamivudine and combination therapy 120
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 120
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 120
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 120
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 119
Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children 118
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 118
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 118
Variants of hepatitis B virus 117
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values 117
Hepatitis B virus surface antigen levels: a guide to sustained response to Peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 117
Hepatitis B virus unable to secrete e antigen 116
A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients 116
Hepatitis C virus infection in type II essential mixed cryoglobulinemias 115
Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay 115
Possible immunopathogenesis for fibrosing cholestatic hepatitis 114
Problems in diagnosing viral hepatitis 114
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C 114
Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B 113
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? 113
Personalized Therapy in chronic viral hepatitis 113
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 113
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients 112
Severe liver injury possibly due to verapamil 111
Validation and comparison of different PCR-based methods for detection of Hepatitis B virus precore region mutants 111
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 110
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 109
Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences 108
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin 107
The natural history of chronic delta hepatitis 107
Comparable function of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors 107
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging 107
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy 105
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic Hepatitis B 104
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. 104
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care' 104
A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combin 104
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C 103
Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies 103
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer 102
Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen 102
Role of hepatitis delta virus infection in hepatocellular carcinoma 101
The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue 101
IN VITRO LIVER MODEL USING MICROFABRICATED SCAFFOLDS IN A MODULAR BIOREACTOR 101
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study 100
Laparoscopic robot-assisted distal splenorenal shunt 100
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 100
Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response 99
Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. 99
The role of quantitative hepatitis B surface antigen revisited 99
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 99
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 98
Uridine diphosphate glucoronosyl transferases, candidate antigens of liver-kidney microsomal antibodies in hepatitis delta virus-infected patients 97
Diagnostic markers of chronic hepatitis B infection and disease” 97
New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases 97
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection 96
Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus 96
Asymptomatic hypermylasemia and hyperlipasemia associated with aripiprazole 96
Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study 96
null 96
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy 96
Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features 95
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. 95
Ruolo degli acidi nucleici e marcatori immunologici nella diagnosi e gestione del portatore cronico di virus epatici maggiori (B, C e D) 95
Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study 95
null 95
Does HBeAg minus HBV modify the course of HDV superinfection? 94
Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? 94
Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis 93
null 93
null 93
Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection 92
Totale 11.413
Categoria #
all - tutte 77.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.262


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.107 0 0 0 0 0 0 0 0 0 0 1.188 919
2019/20207.045 1.020 597 212 480 764 778 769 638 757 431 486 113
2020/20212.917 275 157 204 159 194 123 202 236 356 234 220 557
2021/20224.370 130 272 73 269 776 676 171 200 244 212 161 1.186
2022/20233.206 612 316 204 246 337 453 34 228 525 24 179 48
2023/20242.925 429 311 368 170 489 819 64 74 79 41 81 0
Totale 29.614